Top

Open Access 11-03-2024 | Metastasis | Review

Current pharmacologic treatment of brain metastasis in non-small cell lung cancer

Authors: Takae Okuno, Takeshi Isobe, Yukari Tsubata

Published in: Clinical & Experimental Metastasis

Abstract

Lung cancer is a type of cancer that can metastasize to the lungs, brain, bones, liver, adrenal glands, and other organs; however, the occurrence of brain metastases is the most common event. Symptoms of brain metastasis include motor dysfunction, mental dysfunction, seizures, headaches, nausea, and vomiting, and significantly reduce the quality of life of cancer patients. Brain metastases are a poor prognostic factor, and controlling them is extremely important for prolonging prognosis and improving the quality of life. Currently, local surgery and radiotherapy are recommended for their treatment. However, recently, cancer treatments using molecular-targeted drugs and immune checkpoint inhibitors have been introduced, which may also be effective against brain metastases. Therefore, it is necessary to determine whether local or systemic therapy is optimal for each case. In this review, we focus on recent findings regarding drug therapy in treating brain metastases from advanced non-small cell lung cancer.

Brain Tumor Registry of Japan (2005–2008). 2017 Neurol Med Chir (Tokyo) 57:9–102. https://doi.org/10.2176/nmc.sup.2017-0001

Waqar SN, Samson PP, Robinson CG, Bradley J, Devarakonda S, Du L et al (2018) Non-small-cell lung cancer with brain metastasis at presentation. Clin Lung Cancer 19:e373-379. https://doi.org/10.1016/j.cllc.2018.01.007CrossRefPubMedPubMedCentral

Cagney DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ et al (2017) Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol 1911:1511–1521. https://doi.org/10.1093/neuonc/nox077CrossRef

Gavrilovic IT, Posner JB (2005) Brain metastases: epidemiology and pathophysiology. J Neurooncol 75:5–14. https://doi.org/10.1007/s11060-004-8093-6CrossRefPubMed

Loscalzo J, Fauci A, Kasper D, Hauser S, Longo D, Jameson J (2022) Harrison’s principles of internal medicine, 21e. McGraw Hill, New York

Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W (2008) A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70:510–514. https://doi.org/10.1016/j.ijrobp.2007.06.074CrossRefPubMed

Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X et al (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30:419–425. https://doi.org/10.1200/jco.2011.38.0527CrossRefPubMed

Paul WS, Jonathan Y, Kathryn B, Hubert P, Paul DB, Ananta B et al (2017) Estimating survival in patients with lung cancer and brain metastases an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncol 3:827–831. https://doi.org/10.1001/jamaoncol.2016.3834CrossRef

Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D et al (2022) Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol 40:492–516. https://doi.org/10.1200/jco.21.02314CrossRefPubMed

10.

Le Rhun E, Guckenberger M, Smits M, Dummer R, Bachelot T, Sahm F et al (2021) EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann Oncol 32:1332–1347. https://doi.org/10.1016/j.annonc.2021.07.016CrossRefPubMed

11.

Nabors LB, Portnow J, Ahluwalia M, Baehring J, Brem H, Brem S et al (2020) Central Nervous System Cancers, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 18:1537–1570. https://doi.org/10.6004/jnccn.2020.0052CrossRefPubMed

12.

Maher EA, Mietz J, Arteaga CL, DePinho RA, Mohla S (2009) Brain metastasis: opportunities in basic and translational research. Cancer Res 69:6015–6020. https://doi.org/10.1158/0008-5472.CAN-08-4347CrossRefPubMed

13.

Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ et al (1998) Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280:1485–1489. https://doi.org/10.1001/jama.280.17.1485CrossRefPubMed

14.

Minniti G, Clarke E, Lanzetta G, Osti MF, Trasimeni G, Bozzao A et al (2011) Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol 6:48. https://doi.org/10.1186/1748-717X-6-48CrossRefPubMedPubMedCentral

15.

Greene-Schloesser D, Robbins ME, Peiffer AM, Shaw EG, Wheeler KT, Chan MD (2012) Radiation-induced brain injury: a review. Front Oncol 2:73. https://doi.org/10.3389/fonc.2012.00073CrossRefPubMedPubMedCentral

16.

Dearden S, Stevens J, Wu Y-L, Blowers D (2013) Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol 24:2371–2376. https://doi.org/10.1093/annonc/mdt205CrossRefPubMedPubMedCentral

17.

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH et al (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113–125. https://doi.org/10.1056/NEJMoa1713137CrossRefPubMed

18.

Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y et al (2020) Overall survival with Osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 382:41–50. https://doi.org/10.1056/NEJMoa1913662CrossRefPubMed

19.

Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A et al (2018) CNS response to Osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. https://doi.org/10.1200/JCO.2018.78.3118CrossRefPubMed

20.

Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS et al (2017) Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376:629–640. https://doi.org/10.1056/NEJMoa1612674CrossRefPubMed

21.

Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR et al (2018) CNS efficacy of Osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol 36:2702–2709. https://doi.org/10.1200/JCO.2018.77.9363CrossRefPubMed

22.

Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M et al (2016) Preclinical comparison of Osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res 22:5130–5140. https://doi.org/10.1158/1078-0432.CCR-16-0399CrossRefPubMed

23.

Colclough N, Chen K, Johnström P, Strittmatter N, Yan Y, Wrigley GL et al (2021) Preclinical comparison of the blood-brain barrier permeability of Osimertinib with other EGFR TKIs. Clin Cancer Res 27:189–201. https://doi.org/10.1158/1078-0432.CCR-19-1871CrossRefPubMed

24.

Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S et al (2018) Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol 36:2244–2250. https://doi.org/10.1200/JCO.2018.78.7994CrossRefPubMed

25.

Jung HA, Park S, Lee SH, Ahn JS, Ahn MJ, Sun JM (2023) Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study. ESMO Open 8:102068. https://doi.org/10.1016/j.esmoop.2023.102068CrossRefPubMedPubMedCentral

26.

Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327–3334. https://doi.org/10.1200/JCO.2012.44.2806CrossRefPubMed

27.

Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15:213–222. https://doi.org/10.1016/S1470-2045(13)70604-1CrossRefPubMed

28.

Jin H, Liang P, Hou J, Li B, Wang P, He X (2023) The efficacy and safety of Afatinib in non-small cell lung cancer patients with brain metastasis: a meta-analysis. J Oncol 2023:5493725. https://doi.org/10.1155/2023/5493725CrossRefPubMedPubMedCentral

29.

Schuler M, Wu YL, Hirsh V, O’Byrne K, Yamamoto N, Mok T et al (2016) First-line Afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol 11:380–390. https://doi.org/10.1016/j.jtho.2015.11.014CrossRefPubMed

30.

Tamiya A, Tamiya M, Nishihara T, Shiroyama T, Nakao K, Tsuji T et al (2017) Cerebrospinal fluid penetration rate and efficacy of Afatinib in patients with EGFR mutation-positive non-small cell lung cancer with leptomeningeal carcinomatosis: a multicenter prospective study. Anticancer Res 37:4177–4182. https://doi.org/10.21873/anticanres.11806CrossRefPubMed

31.

Passaro A, Wang J, Wang Y, Lee SH, Melosky B, Shih JY et al (2023) Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol S0923–7534:04281–04283. https://doi.org/10.1016/j.annonc.2023.10.117CrossRef

32.

Hou X, Li M, Wu G, Feng W, Su J, Jiang H et al (2023) Gefitinib plus chemotherapy vs Gefitinib alone in untreated EGFR-mutant non-small cell lung cancer in patients with brain metastases: the GAP BRAIN open-label, randomized, multicenter, Phase 3 study. JAMA Netw Open 6:e2255050. https://doi.org/10.1001/jamanetworkopen.2022.55050CrossRefPubMedPubMedCentral

33.

Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561–566. https://doi.org/10.1038/nature05945CrossRefPubMedADS

34.

Metro G, Tazza M, Matocci R, Chiari R, Crinò L (2017) Optimal management of ALK-positive NSCLC progressing on crizotinib. Lung Cancer 106:58–66. https://doi.org/10.1016/j.lungcan.2017.02.003CrossRefPubMed

35.

Wang W, Sun X, Hui Z (2019) Treatment optimization for brain metastasis from anaplastic lymphoma kinase rearrangement non-small-cell lung cancer. Oncol Res Treat 42:599–606. https://doi.org/10.1159/000502755CrossRefPubMedPubMedCentral

36.

Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND et al (2016) Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol 34:123–129. https://doi.org/10.1200/JCO.2015.62.0138CrossRefPubMed

37.

Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T et al (2017) Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 390:29–39. https://doi.org/10.1016/S0140-6736(17)30565-2CrossRefPubMed

38.

Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW et al (2017) Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377:829–838. https://doi.org/10.1056/NEJMoa1704795CrossRefPubMed

39.

Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ et al (2014) Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 33:1881–1888. https://doi.org/10.1200/JCO.2014.59.0539CrossRef

40.

Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W et al (2011) CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 29:e443–e445. https://doi.org/10.1200/JCO.2010.34.1313CrossRefPubMed

41.

Kodama T, Hasegawa M, Takanashi K, Sakurai Y, Kondoh O, Sakamoto H (2014) Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol 74:1023–1028. https://doi.org/10.1007/s00280-014-2578-6CrossRefPubMed

42.

Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC et al (2014) Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 15:1119–1128. https://doi.org/10.1016/S1470-2045(14)70362-6CrossRefPubMed

43.

Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ et al (2020) Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer: second interim analysis of the phase III ALTA-1L trial. J Clin Oncol 38:3592–3603. https://doi.org/10.1200/JCO.20.00505CrossRefPubMedPubMedCentral

44.

Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ et al (2021) Brigatinib versus crizotinib in ALK inhibitor–naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial. J Thorac Oncol 16:2091–2108. https://doi.org/10.1016/j.jtho.2021.07.035CrossRefPubMed

45.

Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, CROWN Trial Investigators et al (2020) First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med 383:2018–2029. https://doi.org/10.1056/NEJMoa2027187CrossRefPubMed

46.

Soria J-C, Daniel DSW, Chiari R, Wu Y-L, Paz-Ares L, Wolf J, Geater SL et al (2017) First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 389:917–929. https://doi.org/10.1016/S0140-6736(17)30123-XCrossRefPubMed

47.

Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT et al (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863–870. https://doi.org/10.1200/JCO.2011.35.6345CrossRefPubMedPubMedCentral

48.

Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S et al (2012) RET, ROS1 and ALK fusions in lung cancer. Nat Med 18:378–381. https://doi.org/10.1038/nm.2658CrossRefPubMed

49.

Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R et al (2014) Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371:1963–1971. https://doi.org/10.1056/NEJMoa1406766CrossRefPubMedPubMedCentral

50.

Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ et al (2019) Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol 30:1121–1126. https://doi.org/10.1093/annonc/mdz131CrossRefPubMedPubMedCentral

51.

Wu YL, Yang JC, Kim DW, Lu S, Zhou J, Seto T et al (2018) Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer. J Clin Oncol 36:1405–1411. https://doi.org/10.1200/JCO.2017.75.5587CrossRefPubMed

52.

Park S, Ahn BC, Lim SW, Sun JM, Kim HR, Hong MH et al (2018) Characteristics and outcome of ROS1-positive non-small cell lung cancer patients in routine clinical practice. J Thorac Oncol 13:1373–1382. https://doi.org/10.1016/j.jtho.2018.05.026CrossRefPubMed

53.

Metro G, Lunardi G, Floridi P, Pascali JP, Marcomigni L, Chiari R et al (2015) CSF concentration of crizotinib in two ALK-positive non-small-cell lung cancer patients with CNS metastases deriving clinical benefit from treatment. J Thorac Oncol 10:e26–e27. https://doi.org/10.1097/JTO.0000000000000468CrossRefPubMed

54.

Kim YH, Ozasa H, Nagai H, Sakamori Y, Yoshida H, Yagi Y et al (2013) High-dose crizotinib for brain metastases refractory to standard-dose crizotinib. J Thorac Oncol 8:e85–e86. https://doi.org/10.1097/JTO.0b013e31829cebbbCrossRefPubMed

55.

Westphalen CB, Krebs MG, Le Tourneau C, Sokol ES, Maund SL, Wilson TR et al (2021) Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population. NPJ Precis Oncol 5:69. https://doi.org/10.1038/s41698-021-00206-yCrossRefPubMedPubMedCentral

56.

Liu F, Wei Y, Zhang H, Jiang J, Zhang P, Chu Q (2022) NTRK fusion in non-small cell lung cancer: diagnosis, therapy, and TRK inhibitor resistance. Front Oncol 12:864666. https://doi.org/10.3389/fonc.2022.864666CrossRefPubMedPubMedCentral

57.

Dziadziuszko R, Krebs MG, Braud FD, Siena S, Drilon A, Robert C et al (2021) Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion–positive non–small-cell lung cancer. J Clin Oncol 39:1253–1263. https://doi.org/10.1200/JCO.20.03025CrossRefPubMedPubMedCentral

58.

De Carlo E, Bertoli E, Del Conte A, Stanzione B, Berto E, Revelant A et al (2022) Brain metastases management in oncogene-addicted non-small cell lung cancer in the targeted therapies era. Int J Mol Sci 23:6477. https://doi.org/10.3390/ijms23126477CrossRefPubMedPubMedCentral

59.

Planchard D, Besse B, Groen HJM, Hashemi SMS, Mazieres J, Kim TM et al (2022) Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis. J Thorac Oncol 17:103–115. https://doi.org/10.1016/j.jtho.2021.08.011CrossRefPubMed

60.

Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P et al (2016) MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression. J Clin Oncol 34:721–730. https://doi.org/10.1200/JCO.2015.63.4600CrossRefPubMed

61.

Schrock AB, Frampton GM, Suh J, Chalmers ZR, Rosenzweig M, Erlich RL et al (2016) Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations. J Thorac Oncol 11:1493–1502. https://doi.org/10.1016/j.jtho.2016.06.004CrossRefPubMed

62.

Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC et al (2020) Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med 383:931–943. https://doi.org/10.1056/NEJMoa2004407CrossRefPubMedPubMedCentral

63.

Le X, Sakai H, Felip E, Veillon R, Garassino MC, Raskin J et al (2022) Tepotinib efficacy and safety in patients with MET exon 14 skipping NSCLC: outcomes in patient subgroups from the VISION study with relevance for clinical practice. Clin Cancer Res 28:1117–1126. https://doi.org/10.1158/1078-0432.CCR-21-2733CrossRefPubMedPubMedCentral

64.

Takamori S, Matsubara T, Fujishita T, Ito K, Toyozawa R, Seto T et al (2021) Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation. Thorac Cancer 12:978–980. https://doi.org/10.1111/1759-7714.13871CrossRefPubMedPubMedCentral

65.

Tanaka H, Taima K, Makiguchi T, Nakagawa J, Niioka T, Tasaka S (2021) Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation. Cancer Commun (Lond) 41:83–87. https://doi.org/10.1002/cac2.12124CrossRefPubMed

66.

Friese-Hamim M, Clark A, Perrin D, Crowley L, Reusch C, Bogatyrova O et al (2022) Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases. Lung Cancer 163:77–86. https://doi.org/10.1016/j.lungcan.2021.11.020CrossRefPubMed

67.

Dagogo-Jack I, Moonsamy P, Gainor JF, Lennerz JK, Piotrowska Z, Lin JJ, Lennes IT et al (2021) A phase 2 study of capmatinib in patients with MET-altered lung cancer previously treated with a MET inhibitor. J Thorac Oncol 16:850–859. https://doi.org/10.1016/j.jtho.2021.01.1605CrossRefPubMedPubMedCentral

68.

Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, GEOMETRY mono-1 Investigators et al (2020) Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med 383:944–957. https://doi.org/10.1056/NEJMoa2002787CrossRefPubMed

69.

Subbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam F (2020) State-of-the-art strategies for targeting RET-dependent cancers. J Clin Oncol 38:1209–1221. https://doi.org/10.1200/JCO.19.02551CrossRefPubMedPubMedCentral

70.

Drilon A, Subbiah V, Gautschi O, Tomasini P, de Braud F, Solomon BJ et al (2023) Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I/II trial. J Clin Oncol 41:385–394. https://doi.org/10.1200/JCO.22.00393CrossRefPubMed

71.

Subbiah V, Gainor JF, Oxnard GR, Tan DSW, Owen DH, Cho BC et al (2021) Intracranial efficacy of selpercatinib in RET fusion-positive non-small cell lung cancers on the LIBRETTO-001 trial. Clin Cancer Res 27:4160–4167. https://doi.org/10.1158/1078-0432.CCR-21-0800CrossRefPubMedPubMedCentral

72.

Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS et al (2021) Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol 22:959–969. https://doi.org/10.1016/S1470-2045(21)00247-3CrossRefPubMed

73.

Biernacka A, Tsongalis PD, Peterson JD, de Abreu FB, Black CC, Gutmann EJ et al (2016) The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma. Cancer Genet 209:195–198. https://doi.org/10.1016/j.cancergen.2016.03.001CrossRefPubMedPubMedCentral

74.

Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J et al (2021) Sotorasib for lung cancers with KRAS p. G12C mutation. N Engl J Med 384:2371–2381. https://doi.org/10.1056/NEJMoa2103695CrossRefPubMedPubMedCentral

75.

de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M et al (2023) Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet 401:733–746. https://doi.org/10.1016/S0140-6736(23)00221-0CrossRefPubMed

76.

Lamberti G, Aizer A, Ricciuti B, Alessi JV, Pecci F, Tseng SC et al (2023) Incidence of brain metastases and preliminary evidence of intracranial activity with sotorasib in patients with KRASG12C-mutant non-small-cell lung cancer. JCO Precis Oncol 7:e2200621. https://doi.org/10.1200/PO.22.00621CrossRefPubMedPubMedCentral

77.

Vassella E, Kashani E, Zens P, Kündig A, Fung C, Scherz A et al (2021) Mutational profiles of primary pulmonary adenocarcinoma and paired brain metastases disclose the importance of KRAS mutations. Eur J Cancer 159:227–236. https://doi.org/10.1016/j.ejca.2021.10.006CrossRefPubMed

78.

Uy NF, Merkhofer CM, Baik CS (2022) HER2 in non-small cell lung cancer: a review of emerging therapies. Cancers (Basel) 14:4155. https://doi.org/10.3390/cancers14174155CrossRefPubMed

79.

Offin M, Feldman D, Ni A, Myers ML, Lai WV, Pentsova E et al (2019) Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers. Cancer 125:4380–4387. https://doi.org/10.1002/cncr.32461CrossRefPubMed

80.

Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J et al (2022) Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med 386:241–251. https://doi.org/10.1056/NEJMoa2112431CrossRefPubMed

81.

Goto K, Goto Y, Kubo T, Ninomiya K, Kim SW, Planchard D et al (2023) Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 Trial. J Clin Oncol 41:4852–4863. https://doi.org/10.1200/JCO.23.01361CrossRefPubMedPubMedCentral

82.

Yu HA, Goto Y, Hayashi H, Felip E, Chih-Hsin Yang J, Reck M et al (2023) HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy. J Clin Oncol 41:5363–5375. https://doi.org/10.1200/JCO.23.01476CrossRefPubMedPubMedCentral

83.

Mansfield AS, Aubry MC, Moser JC, Harrington SM, Dronca RS, Park SS et al (2016) Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol 27:1953–1958. https://doi.org/10.1093/annonc/mdw289CrossRefPubMedPubMedCentral

84.

Wei Y, Xu Y, Wang M (2023) Immune checkpoint inhibitors for the treatment of non-small cell lung cancer brain metastases. Chin Med J (Engl) 136:1523–1531. https://doi.org/10.1097/CM9.0000000000002163CrossRefPubMed

85.

Pluim D, Ros W, van Bussel MTJ, Brandsma D, Beijnen JH, Schellens JHM (2019) Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid. J Pharm Biomed Anal 164:128–134. https://doi.org/10.1016/j.jpba.2018.10.025CrossRefPubMed

86.

Yan X, Qu F, Zhou Y (2023) Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with brain metastases. Lung Cancer 184:107322. https://doi.org/10.1016/j.lungcan.2023.107322CrossRefPubMed

87.

Gadgeel S, Rodríguez-Abreu D, Speranza G, Esteban E, Felip E, Dómine M et al (2020) Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol 38:1505–1517. https://doi.org/10.1200/JCO.19.03136CrossRefPubMed

88.

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823–1833. https://doi.org/10.1056/NEJMoa1606774CrossRefPubMed

89.

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255–265. https://doi.org/10.1016/S0140-6736(16)32517-XCrossRefPubMed

90.

Nogami N, Barlesi F, Socinski MA, Reck M, Thomas CA, Cappuzzo F et al (2022) IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain. J Thorac Oncol 17:309–323. https://doi.org/10.1016/j.jtho.2021.09.014CrossRefPubMed

91.

Powell SF, Rodríguez-Abreu D, Langer CJ, Tafreshi A, Paz-Ares L, Kopp HG et al (2021) Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases: pooled analysis of KEYNOTE-021, -189, and -407. J Thorac Oncol 16:1883–1892. https://doi.org/10.1016/j.jtho.2021.06.020CrossRefPubMed

92.

Chu X, Niu L, Xiao G, Peng H, Deng F, Liu Z et al (2022) the long-term and short-term efficacy of immunotherapy in non-small cell lung cancer patients with brain metastases: a systematic review and meta-analysis. Front Immunol 13:875488. https://doi.org/10.3389/fimmu.2022.875488CrossRefPubMedPubMedCentral

93.

Reck M, Ciuleanu TE, Lee JS, Schenker M, Zurawski B, Kim SW et al (2023) Systemic and intracranial outcomes with first-line nivolumab plus ipilimumab in patients with metastatic NSCLC and baseline brain metastases from CheckMate 227 Part 1. J Thorac Oncol 18:1055–1069. https://doi.org/10.1016/j.jtho.2023.04.021CrossRefPubMed

94.

Ready NE, Audigier-Valette C, Goldman JW, Felip E, Ciuleanu TE, Rosario García Campelo M et al (2023) First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817. J Immunother Cancer 11:e006127. https://doi.org/10.1136/jitc-2022-006127CrossRefPubMedPubMedCentral

95.

Brahmer JR, Lee JS, Ciuleanu TE, Bernabe Caro R, Nishio M, Urban L et al (2023) Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227. J Clin Oncol 41:1200–1212. https://doi.org/10.1200/JCO.22.01503CrossRefPubMed

96.

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R et al (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377:1919–1929. https://doi.org/10.1056/NEJMoa1709937CrossRefPubMed

97.

El Rassy E, Botticella A, Kattan J, Le Péchoux C, Besse B, Hendriks L (2018) Non-small cell lung cancer brain metastases and the immune system: from brain metastases development to treatment. Cancer Treat Rev 68:69–79. https://doi.org/10.1016/j.ctrv.2018.05.015CrossRefPubMed

98.

Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ et al (2014) Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 74:5458–5468. https://doi.org/10.1158/0008-5472.CAN-14-1258CrossRefPubMed

99.

Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC et al (2017) Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 18:895–903. https://doi.org/10.1016/S1470-2045(17)30380-7CrossRefPubMedPubMedCentral

100.

Altan M, Wang Y, Song J, Welsh J, Tang C, Guha-Thakurta N et al (2023) Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial. J Immunother Cancer 11:e006871. https://doi.org/10.1136/jitc-2023-006871CrossRefPubMedPubMedCentral

Title: Current pharmacologic treatment of brain metastasis in non-small cell lung cancer
Authors: Takae Okuno
Takeshi Isobe
Yukari Tsubata
Publication date: 11-03-2024
Publisher: Springer Netherlands
Keywords: Metastasis
NSCLC
NSCLC
Checkpoint Inhibitors
Osimertinib
Lung Cancer
Lung Cancer
Lung Cancer
CNS Metastasis
Afatinib
Crizotinib
Cytostatic Therapy
Published in: Clinical & Experimental Metastasis
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-024-10276-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Keynote webinar | Spotlight on antibody–drug conjugates in cancer